ASYLIA DIAGNOSTICS
Diagnostics technology platform intended to provide safer immunotherapy for cancer patients.
OUR STORY
Immunotherapy is revolutionizing cancer care. It is rapidly evolving from therapies that nonspecifically stimulate the immune system to more targeted ones that activate individual components of the immune system, increasing the efficacy of the treatment while decreasing toxicity.
​
Despite its tremendous success, immunotherapeutic agents are only successful in a subset of patients and we do not know what defines its success. At Asylia Diagnostics, we believe that high resolution molecular and proteomic tumor microenvironment profiling can shed light and help to stratify patients better. Contact us today to set up a meeting and learn more about partnering opportunities.
WHAT WE DO
At Asylia Diagnostics we are building a technology platform that will permit a quick and efficient high-resolution profiling of tumor microenvironment, different immune cells and their subtypes, and cell signaling. With the right data at hand, it will unlock an opportunity to discover novel biomarkers and modes of action for investigational drugs. Interested to learn more? Get in touch!
NEWS
WHO ARE WE
Asylia Diagnostics is a diagnostics technology platform intended to provide safer immunotherapy for cancer patients. We are focused on developing molecular diagnostics tests to predict response and hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors. Our AI-powered technology platform and knowledge base for discovery and development of molecular biomarkers allows predicting safety risks and efficacy for all solid tumors targeted by immunotherapy.
We will be presenting our pitch at flanders.bio and VIB 6th edition of State of the Union - an event for announcement of new developments and initiatives in the Flemish life sciences cluster.
Read more on
IMEC.ISTART BUSINESS ACCELERATOR PROGRAM
We are excited to announce that we were selected for the imec.istart business accelerator program among other 8 new tech startups.
​
Read more on
WE ARE SUPPORTED BY FLANDERS INVESTMENT & TRADE (FIT)
Flanders Investment & Trade (FIT) are writing about our achievements.
​
Read more on https://www.flandersinvestmentandtrade.com/invest/en/news/imecistart-flanders-attracts-international-start-ups
WE ARE SUPPORTED BY NEW-TECH MAGAZINE
​
New-Tech Magazines - one of the most prominent publisher of hi-tech magazines, producing top quality publications read by more than 70,000 professionals in the country’s innovative electronics, military and technological industries mentioned us in their article about new international tech startups.
Read more on https://www.new-techeurope.com/2019/09/18/imec-istart-supports-nine-new-startups-and-goes-international/
WE ARE A PART OF EIT HEALTH HEADSTART PROGRAM
We are proud to announce that Asylia Diagnosticcs was selected to take part in the annual EIT Health Headstart program. We believe that high resolution molecular and proteomic tumor microenvironment profiling can shed light and help to stratify patients better.
​
Read more on
WE ARE PARTICIPATING IN SUMMER MASSCONNECT® MENTORSHIP CYCLE
We presented our idea of developing molecular diagnostics tests to predict hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors to industry leaders and prospective mentors at MASSACHUSETTS BIOTECHNOLOGY COUNCIL @MassBio®’s MassCONNECT® opening event.
​
Read more
"Above all else, show the data."
Edward R. Tufte
GET IN TOUCH
JLABS @ BE, Janssen Pharmaceutica NV Beerse Site 1, Turnhoutseweg 30, 2340 Beerse, Belgium
+31629946975
